A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial

ConclusionsThis study failed to demonstrate that combined use of ZA and ADT significantly prolonged TTTF in men with treatment-naive prostate cancer and bone metastasis. However, it generates a new hypothesis that the combined therapy could delay the development of castration resistance in a subgroup of patients with low baseline prostate-specific antigen values<200  ng/mL. The treatment also significantly prolonged TTfSRE but did not affect OS.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research